Health Affairs, 25, no. 6 (2006): 1637-1647 doi: 10.1377/hlthaff.25.6.1637 © 2006 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Figures Only Full Text (HTML) Reprint (PDF) Online Appendices Erratum Submit a response to this article Comments: View responses Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Kesselheim, A. S. Articles by Avorn, J. Search for Related Content PubMed PubMed Citation Articles by Kesselheim, A. S. Articles by Avorn, J. Related Collections Legal/Regulatory Issues Medicaid Business Of Health Pharmaceuticals Research And Technology Health Spending

Health Tracking

MARKETWATCH

Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid Spending

Rising prescription drug costs present a critical policy issue for Medicaid. Generic substitution can reduce costs, but the effects are undercut by extensions of intellectual property (IP) protection, elevated generic prices, and low substitution rates. Using Medicaid prescription data for amoxicillin/clavulanate, metformin, and omeprazole, we calculated the savings that could have been realized if generic drugs had been available and fully substituted at their lowest cost when IP protection first expired (an average delay of twenty-six months). The delay in availability, elevated prices, and slow uptake of generic alternatives for these three drugs alone cost Medicaid $1.5 billion in 2000–2004.

                      What's this?

This article has been cited by other articles:

				A. S. Kesselheim and J. Avorn Using Patent Data to Assess the Value of Pharmaceutical Innovation J. Law Med. Ethics, June 1, 2009; 37(2): 176 - 183. [PDF]

				J. Moe, H. Grabowski, D. Ridley, and A. S. Kesselheim FDA Review Vouchers N. Engl. J. Med., February 19, 2009; 360(8): 837 - 838. [Full Text] [PDF]

				A. S. Kesselheim, A. S. Misono, J. L. Lee, M. R. Stedman, M. A. Brookhart, N. K. Choudhry, and W. H. Shrank Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis JAMA, December 3, 2008; 300(21): 2514 - 2526. [Abstract] [Full Text] [PDF]

				A. S. Kesselheim and N. K. Choudhry The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients Ann Intern Med, April 15, 2008; 148(8): 614 - 619. [Abstract] [Full Text] [PDF]

				D. M. Dudzinski and A. S. Kesselheim Scientific and Legal Viability of Follow-on Protein Drugs N. Engl. J. Med., February 21, 2008; 358(8): 843 - 849. [Full Text] [PDF]

Comments: